Du er i ferd med å forlate dette nettstedet.

Dette nettstedet er verken eid eller kontrollert av Pfizer. Pfizer AS er ikke ansvarlig for innholdet på dette nettstedet.

Cancel Ok

Skal vi gjøre screening for å påvise atrieflimmer?

Skal vi gjøre screening for å påvise asymptomatisk atrieflimmer? Foredragsholder  Alf-Åge R Pettersen, Seksjonsoverlege PhD, Hjerteseksjonen, Ringerike sykehus.

Varighet: 32 minutter

Skal vi gjøre screening for å påvise atrieflimmer? (32 min)

I webinaret gjennomgås følgende:

  • Screening for atrieflimmer
  • Metoder for screening
  • Er screening nyttig eller farlig?

 

Foredragsholder: Alf-Åge R Pettersen, Seksjonsoverlege PhD, Hjerteseksjonen, Ringerike sykehus

Webinaret ble sendt første gang i forbindele med markering av Hjertedagen 29. september 2022. 

Referanser:

  • Atrieflimmer og -flutter - NEL - Norsk Elektronisk Legehåndbok (legehandboka.no)
  • Tveit A, Hjerteforum 2011, vol 24
  • Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021 Feb 1;42(5):373-498
  • Friberg. Antikoagulantia till fler kan förebygga många strokefall. Läkartidningen 37/2015;112:DIMU. Lakartidningen.se publisert 2015-09-08
  • Hegbom F, Steen T. 2016 Hjertearytmier.
  • Benjamin EJ, Go AS, Desvigne-Nickens P, Anderson CD, et al.Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2021 Jan 26;143(4):372-388. 
  • Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007 Aug 25;335(7616):383. 
  • Lubitz SA, Atlas SJ, Ashburner JM, Lipsanopoulos ATT, et al. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation. 2022 Mar 29;145(13):946-954. 
  • Svennberg E, Friberg L, Frykman V, Al-Khalili F, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021 Oct 23;398(10310):1498-1506. 
  • Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909-1917. 
  • Abu-Alrub S, Strik M, Ramirez FD, Moussaoui N, et al. Smartwatch Electrocardiograms for Automated and Manual Diagnosis of Atrial Fibrillation: A Comparative Analysis of Three Models. Front Cardiovasc Med. 2022 Feb 4;9:836375. 
  • Rizas KD, Freyer L, Sappler N, von Stülpnagel L, et al. Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med. 2022 Sep;28(9):1823-1830. 
  • Gladstone DJ, Wachter R, Schmalstieg-Bahr K, Quinn FR, et al.. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. JAMA Cardiol. 2021 May 1;6(5):558-567. 
  • Steinhubl SR, Waalen J, Sanyal A, Edwards AM, et al. Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening-mHealth Screening to Prevent Strokes (mSToPS). PLoS One. 2021 Oct 5;16(10):e0258276. 
  • Ausland Å, Sandberg EL, Jortveit J, Seiler S. Heart rhythm assessment in elite endurance athletes: A better method? Front Sports Act Living. 2022 Jul 25;4:937525. 
  • Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021 Oct 23;398(10310):1507-1516.

 

 

PP-ELI-NOR-2319 | Utarbeidet 11.2023

Video: PP-ELI-NOR-2117